Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
White House Appeals To Shared Responsibility For Tackling Flu, Including H1N1, This Fall
White House officials said today that getting ready for the flu in the fall, whether it is seasonal flu or the ongoing H1N1 swine flu outbreak, is a
News of the day
Kenya Malaria Study Shows One-Third Of Patients Receive ACTs
Just about one-third of people seeking malaria treatment in Kenya received the recommended artemisinin-based combination therapies (ACTs) and some people are being treated with ineffective drugs like chloroquine, which was phased out almost 10 years ago, according to the recently launched 2007 Kenya Malaria Indicator Survey - the country"s "first ever comprehensive malaria study," the Daily Nation reports (Gathura/Cheboi, 6/30).
Diagnostics

Which Country Ranks Highest In Biotech Innovation

In a first of its kind study, Scientific American cut through the marketing messages to take a hard look at what countries across the globe are doing to bolster biotech programs within their borders. Many rankings compare Europe, Asia, and the US -- the Scientific American Worldview: A Global Biotechnology Perspective digs deeper, examining all the elements that impact overall biotech innovation. You might be surprised by some of the results. Although it"s probably no surprise that overall, the US had the highest final score, it did not come out on top for all five benchmarks: intellectual property, enterprise support, the intensity of a country"s biotech activities, education/workforce, and infrastructure. - Finland, Israel, Singapore, and Sweden came out on top in terms of the infrastructure available for biotechs. - Singapore and Switzerland scored better than the US when it came to education/workforce. - Iceland ranked highest on the "intensity" score, which measured the intensity -- public companies per capita, portion of overall R&D spending used for biotech, etc. -- of a country"s biotech activities. - Although the US came out on top in intellectual property protections, Belgium, Canada, Denmark, France, Ireland, Italy, Japan, the Netherlands, and the UK weren"t too far behind. The small country of Denmark, however, leads the world in the number of biotech patents per member of the population. To view a complete copy of the report, please visit http://www.saworldview.com. Scientific American


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009